CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to INCY

Phase 3

Development Phase

3

Upcoming Catalysts

0

Historical Events

2

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Q3 '27
INCYPhase 2

Retifanlimab Phase 2 Est. Readout

Retifanlimab
Q3 2027~Q
CT.gov
00%
Q2 '27
INCYPhase 2

Retifanlimab Phase 2 Est. Readout

Retifanlimab
Q2 2027~Q
CT.gov
00%
Jan '27
INCYPhase 2

Retifanlimab Phase 2 Est. Readout (TRICK-MCC)

Retifanlimab
Jan 2027~
CT.gov
00%
Competitive Landscape

1 competitor in Metastatic Merkel Cell Carcinoma

View Full Landscape
Drug Information

Target Indication

Metastatic Merkel Cell Carcinoma

Clinical Trial

NCT03599713

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMAPending

Zynyz

Treatment of locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed on or who are intolerant of platinum-based chemotherapy

View on EMA
EMA4/19/2024

Zynyz

Squamous cell carcinoma of the anal canal (SCAC) Zynyz is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). Merkel cell carcinoma (MCC) Zynyz is indicated as monotherapy for the first line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation therapy.

Orphan
View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.